Tomivosertib Development in Frontline NSCLC Ending After Findings from KICKSTART Trial
Data from the phase 2 KICKSTART trial of tomivosertib plus pembrolizumab do not support the combination's use in patients with non–small cell lung cancer.
Source: onclive.com